✦ LIBER ✦

Abstract #13: Low-Dose Naltrexone's Tolerability and Effects in Fatigued Patients with Parkinson's Disease: An Open-Label Study

✍ Scribed by Thomas Guttuso Jr.; Naomi Salins; David Lichter

Book ID: 116800877
Publisher: Springer-Verlag
Year: 2010
Tongue: English
Weight: 79 KB
Volume: 7
Category: Article
ISSN: 1933-7213
DOI: 10.1016/j.nurt.2010.06.015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Open-label flexible-dose pilot study to

Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease

✍ Joseph H. Friedman; Robert M. Berman; Christopher G. Goetz; Stewart A. Factor; W 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 2 views

## Abstract Psychosis affects at least 5% to 8% of medication‐treated patients with idiopathic Parkinson's disease (PD). Treatment options include reducing medications used for the treatment of PD‐related motor symptoms or introducing an atypical antipsychotic drug. Only clozapine has been demonstr

Long-term safety and tolerability of rot

Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson’s disease: A prospective, open-label extension study

✍ Lawrence W. Elmer; Erwin Surmann; Babak Boroojerdi; Joseph Jankovic 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 408 KB

A 6-month open-label study of the effect

A 6-month open-label study of the effectiveness and tolerability of galantamine in patients with Alzheimer's disease

✍ C.E. Patterson; A.P. Passmore; V.L.S. Crawford 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

Epigenetic and neurological effects and

Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study

✍ Libri, Vincenzo; Yandim, Cihangir; Athanasopoulos, Stavros; Loyse, Naomi; Natisv 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 502 KB

Randomized study of sertraline and low-d

Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life

✍ Angelo Antonini; Silvana Tesei; Anna Zecchinelli; Paolo Barone; Danilo De Gaspar 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 1 views

We assessed the effect of 3-month treatment of sertraline (50 mg) or low-dose amitriptyline (25 mg) on depression and quality of life in 31 patients with Parkinson's disease in a prospective single-blind randomized study. Both drugs significantly reduced the Hamilton Depression Rating Scale (HDRS-17

P.5.a.006 Long-term safety and tolerabil

P.5.a.006 Long-term safety and tolerability of memantine: an open-label extension study in patients with mild to moderate Alzheimer's disease

✍ S. Bakchine; M. Rainer 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 55 KB